Jiri M.
- Country
- Czechia
- Department
- NA
Research Overview
- Effect of Orforglipron on Major Adverse Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
- Evaluation of the Efficacy and Safety of BI 690517 and Empagliflozin in Patients with Symptomatic Heart Failure and LVEF ≥40%: A Phase III Randomized Controlled Trial
- A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation
Data & Insights
Has run more than one trial at 128 of 596 partner sites.
Specializations
Cardiovascular Medicine
The investigator specializes in critical areas of cardiovascular health, with particular emphasis on heart failure management and cardiac rhythm disorders.
- Heart Failure Treatment Innovation
- Left Ventricular Ejection Fraction Management
- Cardiovascular Mortality Prevention
This clinical research focuses on evaluating novel therapeutic approaches for patients with heart failure, particularly those with specific ejection fraction parameters.
Cardiac Electrophysiology
The investigator conducts research in atrial fibrillation management, exploring innovative therapeutic strategies for preventing cardiac complications.
- Stroke Prevention in Atrial Fibrillation
- Cardioembolic Event Management
- Systemic Embolism Prevention
Research activities concentrate on evaluating anticoagulation approaches for patients with cardiac arrhythmias.
Therapeutic Innovation
The investigator evaluates combination therapy approaches in cardiovascular medicine, focusing on novel pharmaceutical interventions.
- Combined Treatment Strategies
- Novel Therapeutic Compounds
- Cardiovascular Drug Development
Research interests include investigating the efficacy of new therapeutic agents in cardiovascular disease management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.